OncUpdates

1.7K posts

OncUpdates banner
OncUpdates

OncUpdates

@OncUpdates

Latest oncology insights for medical professionals and patients| Curating the latest in research, trials & treatment advances| Own Views| Not medical advice

Worldwide Katılım Kasım 2024
728 Takip Edilen905 Takipçiler
OncUpdates retweetledi
Yakup Ergün
Yakup Ergün@dr_yakupergun·
#ESMO26 titles released! We have two meta-analyses addressing dilemmas we frequently encounter in clinical practice: 🔹 In BRAF V600E-mutant NSCLC, should first-line treatment be BRAF/MEK inhibition or an IO-based approach? — with @OncBrothers 💫 🔹 In the neoadjuvant treatment of HER2-positive breast cancer, does adding carboplatin to dual anti-HER2 therapy provide additional benefit? Results at #ESMO26 😊
Yakup Ergün tweet media
ESMO - Eur. Oncology@myESMO

📣 #ESMO26: The place where oncology leaders choose to share their ground-breaking studies. More than 10% increase in abstract submissions compared to 2025. ⏰ Early registration deadline: 22 July 2026 🔗 ow.ly/TyBU50ZgQAm #esmomeetings

English
2
8
60
9.2K
OncUpdates retweetledi
Vincent Rajkumar
Vincent Rajkumar@VincentRK·
This trial shows more is not better. And this is something we have seen in myeloma before. With low dose dex compared to high dose dex. With once weekly bortezomib compared to twice weekly. And more recently with immunotherapy this is even more important. This is another lesson from this trial. @RahulBanerjeeMD @GKaurMD @NorthTxMSG @MyelomaTeacher @JanakiramMurali
English
1
9
35
2.8K
OncUpdates retweetledi
Oncology Brothers
Oncology Brothers@OncBrothers·
3 studies we touched on during our leukemia highlights from @EHA_Hematology #EHA2026 conference with @EuniceWangMD 1. OPTI-AML: 14d vs. 28d Ven (with Aza) 2. KOMET-007: Ziftomenib + 7+3 3. SENTRY: Selinexor + Ruxolitinib #leusm #HemeTwitter #MedX @OncUpdates
Oncology Brothers tweet media
Oncology Brothers@OncBrothers

Leukemia Highlights from #EHA2026 w/ @EuniceWangMD ⭐️ OPTI-AML ⭐️ KOMET-007 ⭐️ SENTRY Full 🗣️ ⭐️ “Oncology Brothers” podcast ⭐️ oncbrothers.com/leukemia-eha20… #HemeTwitter @OncUpdates #OncTwitter #leusm @RoswellPark @EHA_Hematology

English
1
9
17
3.6K
OncUpdates retweetledi
Paolo Tarantino
Paolo Tarantino@PTarantinoMD·
Results from HER2CLIMB-04 show that combining T-DXd with tucatinib does not lead to higher efficacy than T-DXd monotherapy. Follows the disappointing results of HER2CLIMB-02 (T-DM1 + tuc). Tucatinib stabilizes HER2 on the membrane: bad partner for ADCs? clinical-breast-cancer.com/article/S1526-…
Paolo Tarantino tweet media
English
2
25
65
14.4K
OncUpdates retweetledi
Ben Derman
Ben Derman@bdermanmd·
Congratulations to the ENDURANCE investigators on an impactful trial - they should be applauded for running a successful cooperative group phase 3 trial with two randomizations! My thoughts below... ENDURANCE enrolled patients without high-risk disease and without intention for ASCT. The 1st randomization evaluated KRd vs. VRd (no difference in PFS). The 2nd randomization evaluated 2 years vs indefinite lenalidomide maintenance with OS as the primary endpoint. After 9 years of follow-up, there is no difference in OS! Let's dive in and take a closer look... nejm.org/doi/full/10.10…
English
3
10
55
5.8K
OncUpdates
OncUpdates@OncUpdates·
🚨 New @NEJM: Continuous vs 2-Year Fixed Lenalidomide Maintenance in Standard-Risk NDMM ✅ 7-yr OS nearly identical ✅ Fixed-duration may cut toxicity/costs without OS loss 🔑Challenges indefinite maintenance #mmsm #OncTwitter @VincentRK @Myeloma_Doc @OncBrothers @IMFmyeloma
Vincent Rajkumar@VincentRK

Just out!! In @NEJM - Our randomized trial in myeloma (ENDURANCE trial) shows limited duration of lenalidomide maintenance is just as good as indefinite therapy, with less side effects!!! @eaonc @theNCI Implications are HUGE. This is a drug we spends billions on each year: -Less side effects -Less second cancers -Similar overall survival -Less cost @myelomaMD @Myeloma_Doc @SagarLonialMD National NCI funded trial led by @eaonc and joined by @ALLIANCE_org & @SWOG nejm.org/doi/full/10.10…

English
1
4
9
1.6K
OncUpdates retweetledi
Sawyer Bawek, DO
Sawyer Bawek, DO@sawyer_bawek·
#SUCCESSOR-2 highlights from #ASCO26 👇 @ASCO #OncTwitter #MedTwitter #mmsm #MultipleMyeloma #MedX #HemOnc @ASH_hematology
OncUpdates@OncUpdates

⭐️ #ASCO26: MeziKd Doubles PFS in Heavily Pretreated RRMM — SUCCESSOR-2 ✅ PFS: 18.0 vs 8.3 mo ✅ ORR: 80.2% vs 53.4% ✅ ≥CR: 26.7% vs 8.9% ✅ Manageable safety #mmsm #MultipleMyeloma #HemOnc #OncTwitter #Medtwitter @sawyer_bawek 🔗 Full article👇: oncupdates.com/article/asco-2…

English
0
1
5
527
OncUpdates retweetledi
Stephen V Liu, MD
Stephen V Liu, MD@StephenVLiu·
FINALLY! AstraZeneca reaches deal with Dizal to bring sunvozertinib to the US! Approved for EGFR exon 20 NSCLC over a year ago but only available in China (and at a different dose). This deal comes off phase 3 WU-KONG28 showing superiority over 1L chemo. astrazeneca.com/media-centre/p…
Stephen V Liu, MD tweet media
English
6
40
120
12.8K

Keşfet

@SamArmstrongMD @TwoOncDocs @AgrimaMianMD @sawyer_bawek @ASCO @ASH_hematology @OncBrothers @Dr_AmerZeidan